By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
Companion Diagnostics Market Companion Diagnostics Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Companion ...
Prognostic significance of pigmentation and stem cell markers in Indian population of uveal melanoma
Background Increased pigmentation has been associated with cancer stem-cell-like behaviour and chemoresistance in uveal ...
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...
Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback